Industry Symposia

INDUSTRY SYMPOSIA PROGRAM (FRIDAY, MARCH 31, 2023)

Time	Session

13:00 14:00	Advancing care in acute and chronic kidney patients Organized by Baxter Healthcare Watanyu Parapiboon Chairperson Maharat Nakhonratchasima HospitalThailand Welcome and introductions Watanyu Parapiboon Speaker Maharat Nakhonratchasima HospitalThailand A personalised start to life on dialysis: advantages of PD Edwina Brown Speaker e.a.brown@imperial.ac.ukHammersmith HospitalUnited Kingdom Value of CRRT: When, Why & How? Nattachai Srisawat Speaker drnattachai@yahoo.comChulalongkorn University, King Chulalongkorn Memorial HospitalThailand Panel discussion and Q and A Ballroom 1	The Evolving Treatment Landscape in IgA Nephropathy: A Case-Based Discussion Organized by Travere Therapeutics Muh Geot Wong Chairperson University of SydneyAustralia IgA nephropathy: A Deep Dive into The Treatment Landscape Muh Geot Wong Speaker University of SydneyAustralia Panel discussion: Evolving Landscape in IgA Nephropathy Patient Management Muh Geot Wong Speaker University of SydneyAustralia Sian Griffin Speaker Vivekanand Jha Speaker vjha@georgeinstitute.org.inThe George Institute for Global HealthIndia MR 109 ABFE	SGLT2 inhibitors: A driving force to improved standard-of-care in CKD Organized by Science Collected. Supported by an unrestricted educational grant from AstraZeneca Carol Pollock Chairperson University of SydneyAustralia Welcome and Introductions Carol Pollock Speaker University of SydneyAustralia Three-pronged protection – mortality, cardiovascular, and kidney benefits with SGLT2 inhibitors Sydney Tang Speaker The University of Hong KongHong Kong, China Old problems, new solutions – practical approaches to optimising care Carol Pollock Speaker University of SydneyAustralia Is it too late? An opportunity to intervene early Mustafa Arici Speaker Panel discussion and Q and A Closing remarks Carol Pollock Speaker University of SydneyAustralia MR 109 CDHG	Chinook Therapeutics: Changing the Course of Kidney Care Organized by Chinook Therapeutics Adrian Liew Chairperson draliew2@gmail.comMount Elizabeth Novena HospitalSingapore Atrasentan for the Treatment of IgA Nephropathy: Interim Results from the AFFINITY Study Adrian Liew Speaker draliew2@gmail.comMount Elizabeth Novena HospitalSingapore Updated Interim Results of a Phase 1 / 2 Study of BION-1301 in Patients with IgA Nephropathy Hernan Trimarchi Speaker HOSPITAL BRITANICO DE BUENOS AIRESArgentina MR 110	C3G and IC-MPGN: Current state of evidence and how to tackle challenges in clinical management Organized by Novartis Edwin Wong Speaker Masashi Mizuno Speaker Welcome and introduction Diagnostic challenges of C3G and IC-MPGN Marina Vivarelli Speaker Treatment approaches in C3G and IC-MPGN: Today and tomorrow Edwin Wong Speaker Q and A Closing Remarks Edwin Wong and Masashi Mizuno MR 111	Evolving Landscape in IgA Nephropathy Patient Management Organized by Calliditas Therapeutics Jonathan Barratt Chairperson Welcome and Introductions Jonathan Barratt Speaker Perspectives on Why IgA Nephropathy is a Mucosal Auto-immune Disease Yusuke Suzuki Speaker Juntendo University School of MedicineJapan Evolving Considerations of Recent Advances in IgA Nephropathy Management See Cheng YEO Speaker Updates on Emerging Therapies in IgA Nephropathy eGFR vs. Proteinuria Jonathan Barratt Speaker Panel Q and A: Evolving Landscape in IgA Nephropathy Patient Management Plenary Hall 1
17:00 18:00	Evidence Based Treatment of Anemia in CKD: Focus on HIF-PHIs Organized by Zydus Lifesciences Brief overview - Anemia in CKD Sanjeev GULATI Speaker Managing Anemia in CKD with HIF PHIs - What Does Recent Evidence Tell Us? Dinesh Khullar Speaker Panel discussion: The Way Forward for HIF PHIs - Evidence to Clinical Practice Vijay Kher Moderator Anil Bhalla Panelist Ashwani Gupta Panelist Dibya Singh Shah Panelist Institute of Medicine ,Tribhuvan University Teaching HospitalNepal Dilip Kumar Pahari Panelist Manisha Sahay Panelist Osmania General HospitalIndia Narayan Prasad Panelist Sanjay Gandhi Post Graduate Institute of Medical SIndia Prem Varma Panelist Raj Kumar Sharma Panelist Urmila Anandh Panelist Amrita HospitalsIndia MR 109 ABFE		Optimizing Nutritional Therapy with Ketoanalogues in CKD Patients Organized by Fresenius Kabi Giorgina Barbara Piccoli Chairperson Hallmarks of Nutritional Strategies to Delay Dialysis in CKD Patients Kamyar Kalantar-Zade Speaker kamyar@dispostable.com Clinical Role of Ketoanalogues: Real-world Evidences and Perspectives Maiszu WU Speaker How to Implement Supplemented Protein- restricted Diets in Clinical Practice Giorgina Barbara Piccoli Speaker Q and A MR 109 CDHG		Developments Into Expanding the Understanding of Anemia in CKD Supported by GSK Roberto Pecoits Filho Chairperson Arbor Research Collaborative for HealthUnited States About ISN iNET-CKD Maarten Taal Speaker Results from the international variation in Hb study Adeera Levin Speaker University of British ColumbiaCanada New study into longitudinal changes in Hb Maarten Taal Speaker Q and A Closing remarks Maarten Taal Speaker MR 111